Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 80,200 shares, a growth of 27.7% from the October 15th total of 62,800 shares. Based on an average daily volume of 120,000 shares, the days-to-cover ratio is presently 0.7 days.
Coloplast A/S Stock Up 2.7 %
CLPBY traded up $0.34 during trading on Friday, reaching $12.88. The company’s stock had a trading volume of 89,996 shares, compared to its average volume of 76,532. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.85 and a quick ratio of 0.56. The company’s fifty day moving average price is $13.14 and its 200-day moving average price is $12.85. Coloplast A/S has a 52-week low of $10.57 and a 52-week high of $14.34.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share for the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 31.17%. The business had revenue of $1.02 billion for the quarter. Research analysts forecast that Coloplast A/S will post 0.38 earnings per share for the current fiscal year.
Coloplast A/S Increases Dividend
Coloplast A/S Company Profile
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.
Read More
- Five stocks we like better than Coloplast A/S
- How to Capture the Benefits of Dividend Increases
- Top-Performing Non-Leveraged ETFs This Year
- Conference Calls and Individual Investors
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Pros And Cons Of Monthly Dividend Stocks
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.